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Background: Antibiotic use (ABU) surveillance in healthcare facilities (HCFs) is essential to guide stewardship.
Two methods are recommended: antibiotic consumption (ABC), expressed as the number of DDD/1000 patient-
days; and prevalence of antibiotic prescription (ABP) measured through point prevalence surveys. However, no
evidence is provided about whether they lead to similar conclusions.
Objectives: To compare ABC and ABP regarding HCF ranking and their ability to identify outliers.
Methods: The comparison was made using 2012 national databases from the antibiotic surveillance network
and prevalence study. HCF rankings according to each method were compared with Spearman’s correlation co-
efficient. Analyses included the ABU from entire HCFs as well as according to type, clinical ward and by antibiotic
class and specific molecule.
Results: A total of 1076 HCFs were included. HCF rankings were strongly correlated in the whole cohort. The cor-
relation was stronger for HCFs with a higher number of beds or with a low or moderate proportion of acute care
beds. ABU correlation between ABC or ABP was globally moderate or weak in specific wards. Furthermore, the
two methods did not identify the same outliers, whichever HCF characteristics were analysed. Correlation be-
tween HCF ranking varied according to the antibiotic class.
Conclusions: Both methods ranked HCFs similarly overall according to ABC or ABP; however, major differences
were observed in ranking of clinical wards, antibiotic classes and detection of outliers. ABC and ABP are two
markers of ABU that could be used as two complementary approaches to identify targets for improvement.
Introduction
Antibiotic resistance is spreading all around the world and rep-
resents a threat for global health.1 Antibiotic misuse is a known
key determinant of antibiotic resistance development.2,3 Thus,
antibiotic stewardship aims to improve antibiotic prescription
management and reduce unnecessary or excessive antibiotic
use.4 Antibiotic use (ABU) surveillance networks help health-
care facilities (HCFs) to produce appropriate data to compare
themselves with others and to monitor trends, in order to
implement targeted antibiotic stewardship. In addition, the
surveillance networks allow the identification of HCFs with
the highest ABU, so-called outlier HCFs.
Antibiotic consumption (ABC) is generally measured as the
number of DDD/1000 patient-days (PD), as recommended by the
WHO using the Anatomical Therapeutic Chemical (ATC) index.5 In
addition, the European Surveillance of Antimicrobial Consumption
(ESAC) programme has implemented point prevalence surveys
(PPSs) as an alternative method.6–8 PPSs measure ABU as antibiotic
prevalence (ABP), defined as the prevalence of inpatients receiving
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at least one antibiotic agent on the day of the survey. Those two
methods, ABC and ABP, are proposed to measure ABU. However, to
the best of our knowledge, these two methods have never been
evaluated in relation to each other, in terms of ranking HCFs
according to their ABU, or to define which HCFs may be identified
as ABU outliers.
In France, a national antibiotic consumption surveillance, called
ATB-Raisin, has been implemented in all voluntary HCFs since
2007, providing ABC data every year.9 Also, a national hospital-
acquired infection and ABU PPS is conducted every 5 years in al-
most every HCF in France, providing ABP data.10 The objective of
this study was to compare ABC and ABP for HCF ranking as well as
for the identification of outliers using the 2012 hospital data from
ATB-Raisin and the national prevalence survey.
Methods
Data source
ATB-Raisin, the French hospital ABC surveillance network, has been imple-
mented since 2007 and is described elsewhere.11 It aims to collect ABC
data and to describe patterns of consumption, in order to identify room for
improvement. Participation is voluntary and requires HCFs to provide struc-
tural elements (hospital type, number of beds, number of PDs, type of activ-
ities, etc.) in addition to data about ABC for the whole HCF and by type of
ward (i.e. medicine, surgery, ICU, gynaecology, psychiatry, rehabilitation,
long-term care). ABC from 1 January to 31 December was retrospectively
collected. ABC data were expressed as a distribution (median, IQR). Tukey
box plots were used to show selected percentiles and outside values and
for comparing distribution.12,13 ABC outliers were defined as follows: an HCF
where ABC was greater than 1.5 times the IQR above the upper quartile
[meaning higher than p75!1.5% (p75#p25), where p75 and p25 are the
75th and the 25th percentiles of ABC distribution, respectively] was called a
‘superior outlier’; an HCF where ABC was lower than 1.5 times the IQR below
the lower quartile [meaning lower than p25#1.5% (p75#p25)] was
called an ‘inferior outlier’. These HCFs whose consumption was significantly
different from that of the other HCFs were individually warned about their
status to help them implement antibiotic stewardship measures.
A national hospital-acquired infection and ABU prevalence study is
conducted every 5 years in France. The last PPS proposed to every French
HCF was conducted in 2012 (14 May to 29 June).14 In addition to the same
structural data as in ATB-Raisin, HCFs had to provide data about every in-
patient present before 8 am on the day of the survey. All inpatient units
were considered, including acute care, rehabilitation care and long-term
care units. All antibiotics prescribed on this day were recorded. ABP outliers
were identified with the same definition as the ATB-Raisin survey.
The daytime hospitalization sector and nursing homes were not
included in either survey. Data for the year 2012, the last one with available
data for both the PPS (for ABP) and ATB-Raisin surveillance network
(for ABC), were included in this study.14
Quantification of antimicrobial source
In the ATB-Raisin network, ABC was expressed as the number of DDD/
1000 PD, according to the WHO/ATC 2012 index, the DDD being
the assumed average maintenance dose per day for a drug used for its
main indication in a 70 kg adult. In the PPS, results were expressed using
prevalence (ABP), which represented the proportion of patients receiving at
least one antimicrobial agent among the totality of the inpatients (preva-
lence of treated patients). HCFs that had included fewer than 20 inpatients
in the PPS were excluded from the study.
Selection of antibiotics
ABU was analysed according to the therapeutic categories defined in the
WHO/ATC 2012 index.
Some selected molecules frequently used or considered as critical for
antibiotic resistance selection were tested on their own.
Statistical analysis
HCFs were ranked according to their ABU expressed as ABC on one hand
and as ABP on the other hand, for overall ABU and per selected drugs. Each
HCF had a unique identifying number allowing comparisons between ABC
and ABP. Comparisons focused on HCF ranking rather than actual ABC or
ABP values. The two ways of HCF ranking were compared using Spearman’s
rank correlation, which is a Pearson correlation coefficient calculated with
the ranks of the values of each of the two variables, instead of their actual
values.15 No assumption was made about the distribution of the data.
A correlation was considered as very strong (linear) if the correlation coeffi-
cient q was0.8, strong if 0.6q , 0.8, moderate if 0.4q , 0.6 and weak
if q , 0.4. To take into account HCF characteristics, the correlation was also
analysed according to: HCF type, in reference to French administrative clas-
sification (including teaching and non-teaching hospitals); size; and
the clinical activity of the wards (i.e. medicine, surgery, gynaecology,
rehabilitation, long-term care, psychiatry).16 Comparisons were also per-
formed per selected antibiotic or antibiotic class. Stata software version
11.0 (StataCorp, College Station, TX, USA) was used for all analyses.
A P value of ,0.05 was considered statistically significant.
Results
Selection and description of participating hospitals
For the year 2012, a total of 1411 HCFs participated in ATB-Raisin,
whereas 1938 participated in the PPS. Among them, 1076 HCFs
participated in both. This included 328 non-teaching public hospi-
tals, 276 non-teaching private hospitals, 241 rehabilitation centres,
99 psychiatric hospitals, 68 local hospitals, 36 teaching hospitals,
11 cancer hospitals, 10 long-term care units and 7 military teach-
ing hospitals (Table 1). Facilities were public (46.4%), private
(35.7%) and private ‘not for profit’ (17.9%). There were as many
hospitals including 100 beds (39.7%) as hospitals including
101–300 beds (40.3%), whereas hospitals including .300 beds
constituted a minority (20.0%; Table 2).
HCF ranking by global consumption and identification of
outliers
ABC ranged from 2.33 to 1133.87 DDD/1000 PD [median 299.91,
IQR (157.07–468.86)] whereas ABP ranged from 0% to 49.23%
[median 13.94, IQR (7.00–20.75)] (Figure 1). HCF ranking according
to either ABC or ABP was strongly correlated (q"0.79, P10#4),
as shown in Figure 2. However, HCFs with the highest and lowest
ABU differed according to either ABC or ABP. In addition, 39 HCFs
had a zero ABP, including 14 psychiatric and 10 rehabilitation HCFs,
while only 14 of them (35.9%) were among the 50 HCFs with
the lowest ABC. Among the 50 HCFs with either the highest ABC or
ABP, only 5 (10%) were common to the two methods. No HCF
was identified as an inferior outlier, meaning that none of them
was prescribing less than the rest of the group [i.e. ABC or
ABP , p25#1.5% (p75#p25)] with either method.
Among the nine HCFs considered outliers for ABP (0.84% of the
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other hand, five HCFs (0.46% of the total) were identified as out-
liers for ABC, while four of them (80.0%) were not detected as such
for ABP. Both ABC and ABP methods defined only one HCF as an
outlier in common (1 of 13; 7.69%).
HCF ranking according to type
HCF ranking according to ABC or ABP correlated for all HCFs, re-
gardless of their status: Spearman’s correlation coefficient was
equal to 0.83 for public, 0.79 for private ‘not for profit’ and 0.71
for private ‘for profit’ facilities. According to the HCF type, the
correlation coefficient between ranking for each method went
from low (psychiatric facilities, q"0.33) to very high values
(teaching public hospitals, q"0.87; Table 2). Detailed data on
type are available (Figure S1, available as Supplementary data
at JAC-AMR online).
HCF ranking according to size and clinical activity
Spearman’s correlation coefficient was very strong for HCFs with
.300 or with 101–300 beds (q"0.81 for both), whereas it was
strong for HCF with 100 beds (q"0.69; Table 2). The correlation
between ABC and ABP varied according to the proportion of acute
care beds: strong for HCFs with a low or moderate proportion of
acute care beds (q"0.69 and 0.66, respectively), whereas moder-
ate when this proportion was more than 66% (q"0.46). Median
ABU per ward was highest according to both ABP and ABC for ICU,
medicine and surgery and lowest for psychiatry (also according to
both methods; Table 3). However, the ranking differed for paediat-
ric, gynaecology/obstetric, long-term care and rehabilitation
wards. Spearman’s correlation coefficient was globally moderate
(rehabilitation and medicine units) or weak (ICU, surgery, paediat-
ric, gynaecology/obstetric, psychiatric and long-term care units).
The proportion of HCFs identified as outliers for ABC ranged from
Table 1. Description of participating HCFs
Number (%) of participating HCFs Number of beds, median (IQR)
Type
military teaching hospitals 7 (0.7) 229 (196–296)
teaching hospitals, public 36 (3.3) 825 (388–1386)
non-teaching hospitals, public 328 (30.5) 247 (134–450)
non-teaching hospitals, private 276 (25.7) 131 (85–201)
cancer hospitals 11 (1.0) 118 (79–167)
rehabilitation centres 241 (22.4) 85 (60–111)
local hospitals 68 (6.3) 52 (34–70)
long-term care hospitals 10 (0.9) 63 (30–80)
psychiatric hospitals 99 (9.2) 155 (79–322)
Status
public 499 (46.4) 226 (91–435)
private ‘for profit’ 384 (35.7) 98 (70–153)
private ‘not for profit’ 193 (17.9) 106 (75–180)
Table 2. Spearman’s correlation coefficient between HCF ranking according to ABU expressed as consumption in DDD/1000 PD or as prevalence,
according to different facilities’ characteristics
n (%) ABC (DDD/1000 PD), median (p25–p75) ABP (%), median (p25–p75) q P
Type
non-teaching, public 328 (30.5) 419.3 (313.0–520.5) 23.5 (17.8–30.0) 0.72 ,10#4
non-teaching, private 276 (25.7) 436.1 (333.5–526.8) 23.1 (16.3–31.5) 0.36 ,10#4
rehabilitation 241 (22.4) 165.4 (112.2–214.7) 9.1 (5.6–13.5) 0.51 ,10#4
psychiatric 99 (9.2) 51.2 (35.8–68.6) 2.4 (1.1–3.3) 0.33 ,10#4
local 68 (6.3) 173.7 (139.6–228.8) 10.0 (4.9–17.4) 0.41 ,10#4
teaching, public 36 (3.3) 550.1 (384.5–680.7) 32.3 (22.6–37.3) 0.87 ,10#4
cancer centre 11 (1.0) 419.9 (358.1–521.4) 32.9 (27.0–36.4) 0.55 ,10#4
long-term care 10 (0.9) 83.1 (50.6–119.3) 3.0 (0.0–9.4) 0.74 ,10#4
military teaching 7 (0.7) 550.3 (531.4–693.4) 35.5 (27.8–44.8) 0.75 ,10#4
Size
100 beds 427 (39.7) 194.3 (119.7–314.6) 11.1 (5.5–20.9) 0.69 ,10#4
101–300 beds 434 (40.3) 357.3 (189.4–492.0) 19.1 (10.4–27.8) 0.81 ,10#4
.300 beds 215 (20.0) 442.2 (321.4–536.3) 25.2 (17.0–30.5) 0.81 ,10#4
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0.61% (ICU) to 4.78% (long-term care) and for ABP from 0.0%
(ICU) to 4.19% (rehabilitation centres). Most outliers defined by
one method were not outliers for the other (between 8.9% and
100%). Hence, the proportion of HCFs identified as outliers by both
ABC and ABP was null for ICU, surgery, paediatric and psychiatric
wards and peaked at 11.11% for medicine wards (Table 3).
HCF ranking according to antibiotic or antibiotic class
As shown in Table 4 and Table S1, the correlation between HCF
ranking according to either ABC or ABP was very strong for b-lac-
tams (q"0.81) and strong for aminoglycosides, quinolones and
fluoroquinolones (q"0.69 for each). This correlation was weaker
for glycopeptides (q"0.62), carbapenems (q"0.57) and the mac-
rolides, lincosamides and streptogramins class (q"0.51). Among
b-lactams, the correlation was lower for amoxicillin (q"0.47) than
for other antibiotics: q"0.65 for piperacillin/tazobactam; q"0.72
for amoxicillin/clavulanic acid; and q"0.78 for IV third-generation
cephalosporins (IV 3GCs). An important proportion of HCFs were
identified as outliers by one or both methods: with ABC, 12.7%
and 10.5% of the HCFs for aztreonam and piperacillin/tazobactam,
respectively; with ABP, 24.7% and 22.4% of the HCFs for carbape-
nems and pseudomonal 3GCs, respectively. The proportion of HCFs
identified as outliers by both methods ranged from 0% (b-lactams)
to 42.6% (piperacillin/tazobactam). This proportion was notably
small for IV 3GCs, amoxicillin and fluoroquinolones (4.55%, 5.26%
and 5.26%, respectively). Overall, for several antibiotics or antibiot-
ic classes, ABP identified more outliers than ABC.
Discussion
Our results showed a strong correlation of both ABU ranking meth-
ods. This correlation was strong for all HCFs and one could assume
that ABC and ABP are interchangeable. However, several issues
might challenge this statement.
First, when HCFs were stratified by HCF type or clinical ward, the
correlation was less pronounced. Particularly, it was lower in HCFs
with the highest proportion of acute care beds. This could be due
to the variability of the inpatient profile on the day of the survey. It
might also be due to seasonal differences in ABU. ABC data include
yearly consumption while ABP data were collected at the end of
spring. Besides, the ABP calculation method does not take into
account multiple drugs on the day of the survey, while the ABC
method includes all antibiotic consumption.
On the other hand, the ranking of HCFs according to ABC or to
ABP in psychiatric and rehabilitation HCFs correlated poorly. Patients
hospitalized in these HCFs infrequently need antibiotic treatment,
which may explain the null ABP observed in some HCFs. Thus, vari-
ability in ABU in these settings may be due to few patients requiring
antibiotics. Likewise, ward ranking by ABP correlated poorly since
ABP is uncertain owing to the small ward size, leading to a wide ABP
variability. However, both methods identified the same wards with
the highest (ICU, medicine, surgery) and lowest (psychiatry) ABU,





































Figure 1. Distribution of antibiotic use in HCFs according to ABC (left
panel) or ABP (right panel). Central lines, boxes and whiskers represent
the median, IQR (Q3–Q1) and 1.5 times the IQR below the lower quartile
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Second, regarding specific antibiotics or antibiotic classes,
ABC and ABP provided diverging results as well. Among the most
commonly used antibiotics such as b-lactams or fluoroquinolones,
there was generally a correlation between both methods. The
correlation was weaker for antibiotics with low use such as pseu-
domonal 3GCs, carbapenems or aztreonam. However, even for
amoxicillin, one of the top prescribed antibiotics, we did not
observe a linear relationship between ranking per consumption
and prevalence. One explanation could be that the amoxicillin
DDD (i.e. 1 g in 2012, when data were recorded) did not accurately
reflect the actual prescribed dose, which is at least 3 g for adult
patients in French HCFs. The recent DDD modification to 1.5 g and
3 g for oral and injectable formulations, respectively, should min-
imize this discrepancy in the future, though 1.5 g still remains
below the prescribed dose in most cases.5
For less commonly prescribed antibiotics (such as pseudomonal
3GCs, carbapenems or glycopeptides), more outliers were
identified with ABP than with ABC. Again, the gap between the two
methods could be explained by the selection of inpatients who
may not necessitate these kinds of antibiotic on the given day the
prevalence study was performed. Furthermore, there is a random
effect, inherent to a 1 day prevalence survey, and this effect could
be major for infrequently used drugs.
Third, the two methods did not identify the same highest
prescribers. Besides, most of these HCFs were outliers only with
one method. However, the proportion of clinical wards defined as
outliers was below 5%, whatever the method used, and thus the
impact of the disagreement between both methods was probably
minimal. Seeing these results, we wonder if the criteria for defining
outliers should not be changed by using a wider IQR (e.g. 10th to
90th percentiles) to select HCFs really differing from the group.
The interest in identifying potential inferior outliers for the
global ABU is secondary compared with the superior outliers and
the aim should not be to warn an HCF but to salute its antibiotic
stewardship. The fact that none of the HCFs was defined in this
way is consistent with the difficulty in significantly reducing the
ABU compared with the vast majority of HCFs.
Since DDD does not reflect the recommended or prescribed
dose for some of the most commonly prescribed drugs such as
amoxicillin, many authors have tried to define a better indicator to
estimate ABC.17–24 DDDs were not developed to reflect prescribed
doses or prescription quality but to compare consumption data. In
addition, the information regarding the anatomical site or the se-
verity of infection is not available. The use of PD as the denomin-
ator has also been questioned by several authors and, in some
cases, other units seemed more relevant according to the type of
structure, such as the number of admissions or the finished con-
sultant episode.25–27
Implications for data surveillance
DDD/1000 PD is currently the gold standard for ABU evaluation to
allow benchmarking between different HCFs and countries.28,29
ABC has the advantage of being easily collected and provides year-
ly data.
On the other hand, PPSs provide an overview of the current situ-
ation in HCFs and are dedicated to collecting patient and indication
characteristics as well as information on antibiotic utilization (dos-
age, administration rhythm, duration of therapy) at the time of the
survey. PPSs are feasible with limited resources.7 Repeated surveys,
be they local or European, allow estimation of a trend of overall
ABU evolution and are sometimes the only source of information
for countries that don’t have a national surveillance network.28,30
However, these surveys are only carried out in a given period,
which limits the extrapolation for the entire year when patterns of
infection are different due to seasonal variations. Furthermore,
the HCFs participating in these surveys have different skills and
the evaluation and grading might not be reproducible.
Table 3. Spearman’s correlation coefficient between HCF ranking according to antibiotic global use expressed as consumption in DDD/1000 PD or as
prevalence, distribution and proportion of outliers defined by both methods, according to clinical ward
Ward n q P



























Medicine 440 0.49 ,10#4 409 (342–526) 0.9 (4) 75 19.6 (10.3–28.0) 1.4 (6) 83 11.1
ICU 165 0.32 ,10#4 1246(736–1538) 0.6 (1) 100 35.3 (27.3–57.9) 0 (0) — 0
Surgery 337 0.39 ,10#4 475 (353–560) 1.2 (4) 100 19.5 (13.4–28.1) 1.5 (5) 100 0
Paediatric 167 0.38 ,10#4 169 (130–280) 1.8 (3) 100 2.1 (0.0–20.0) 1.8 (3) 100 0
Gynaecology-
obstetric
254 0.25 ,10#4 241 (211–308) 3.5 (9) 8.9 4.5 (0.0–11.1) 3.9 (10) 90 5.6
Psychiatric 193 0.25 ,10#4 36 (22–51) 1.6 (3) 100 1.7 (0.0–2.6) 1.6 (3) 100 0
Long-term
care
230 0.26 ,10#4 72 (26–77) 4.8 (11) 91 2.5 (0.0–4.1) 3.9 (9) 89 5.3
Rehabilitation 597 0.50 ,10#4 162 (108–211) 2.5 (15) 80 7.7 (4.7–11.1) 4.2 (25) 88 8.1
aProportion of outliers according to both methods" (outliers in ABC and ABP)/(outliers in ABC and ABP!outliers in ABC!outliers in ABP).
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At least two objectives of an ABU surveillance network can be
defined.
• First, to provide ABU data at a regional, national or international
level. These data are used by stakeholders, health authorities
and HCFs to help them define and implement antibiotic
policies.11,31 In France, the regional centres for healthcare-
associated infection prevention (CPias) play an important role
in helping HCFs analyse their prescribing practices and imple-
ment stewardship measures. In this regard, ABC and ABP seem
to provide equivalent results.
• Second, to identify and individually warn HCFs with ABU
higher than other similar HCFs (so-called outliers). This
warning is assumed to help them implement and target
local antibiotic stewardship.32–34 In this regard, ABC and ABP
seem to provide divergent results by identifying different
outliers.
This study is based on 2012 data, i.e. the latest data on ABP
available in a large number of HCFs in France. To our knowledge, it
is the first to compare the ABC and the ABP surveys, on a 1 year
dataset from a national surveillance network and a PPS, in the
same subset of more than 1000 HCFs. A large HCF participation in
both surveys provided a strong database and ensured an appropri-
ate representation of the French healthcare landscape in terms of
status, geographic location, size and activities. Whether the same
results would be observed in a different setting needs further
investigations.
Conclusions
In conclusion, these data show that ABC and ABP globally meas-
ured ABU in the same way, but diverged at the clinical ward or anti-
biotic level, as well as identifying different outliers. Our study was
not designed to determine whether one was a better method than
the other, but rather to compare them on the same set of data.
Therefore, ABC and ABP could be used in a complementary way,
keeping in mind these nuances when analysing antibiotic con-
sumption data.
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Table 4. Spearman’s correlation coefficient between HCF ranking according to antibiotic global use expressed as consumption (ABC) or as prevalence
(ABP) and proportion of outliers in ABC and in ABP, according to main antibiotic groups
q P
























0.79 ,10#4 0.5 (5) 80 0.8 (9) 88.9 7.7 (1)
Amoxicillin 0.47 ,10#4 2.9 (31) 90.3 2.7 (29) 89.7 5.3 (3)
Amoxicillin/clavulanic
acid
0.72 ,10#4 0.9 (10) 80 1.9 (20) 90 7.1 (2)
Piperacillin/tazobactam 0.65 ,10#4 10.5 (113) 21.2 17.2 (185) 51.9 42.6 (89)
IV pseudomonal 3GCsa 0.55 ,10#4 8.0 (86) 24.4 22.4 (241) 73.0 24.8 (65)
IV non-pseudomonal
3GCsb
0.78 ,10#4 1.1 (12) 91.7 1.1 (12) 91.7 4.4 (1)
Carbapenems 0.57 ,10#4 7.9 (85) 24.7 24.7 (266) 75.9 22.3 (64)
Aztreonam 0.24 ,10#4 12.7 (137) 92.7 1.1 (12) 16.7 7.2 (10)
Tetracyclines 0.35 ,10#4 6.5 (70) 57.1 15.8 (170) 82.4 14.3 (30)
Sulphonamides 0.50 ,10#4 4.2 (45) 57.8 6.6 (71) 73.2 19.6 (19)
MLS 0.51 ,10#4 2.6 (28) 67.9 3.4 (36) 75 16.4 (9)
Aminoglycosides 0.69 ,10#4 3.6 (39) 59.0 6.7 (72) 77.8 16.8 (16)
Fluoroquinolones 0.69 ,10#4 1.8 (19) 89.5 2.0 (21) 90.5 5.3 (2)
Glycopeptides 0.62 ,10#4 6.0 (64) 40.6 11.0 (118) 67.8 26.4 (38)
Imidazole derivatives 0.70 ,10#4 2.7 (29) 58.6 4.0 (43) 72.1 20.0 (12)
Antibiotics for MRSAc 0.64 ,10#4 6.1 (66) 39.4 9.4 (101) 60.4 31.5 (40)
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17 Watier L, Cavalié P, Coignard B et al. Comparing antibiotic consumption
between two European countries: are packages an adequate surrogate for
prescriptions? Euro Surveill 2017; 22: 17-00352.
18 Haug JB, Reikvam A. WHO defined daily doses versus hospital-adjusted
defined daily doses: impact on results of antibiotic use surveillance. J
Antimicrob Chemother 2013; 68: 2940–7.
19 de With K, Bestehorn H, Steib-Bauert M et al. Comparison of defined ver-
sus recommended versus prescribed daily doses for measuring hospital anti-
biotic consumption. Infection 2009; 37: 349–52.
20 Gagliotti C, Ricchizzi E, Buttazzi R et al. Hospital statistics for antibiotics:
defined versus prescribed daily dose. Infection 2014; 42: 869–73.
21 Muller A, Monnet DL, Talon D et al. Discrepancies between prescribed
daily doses and WHO defined daily doses of antibacterials at a university hos-
pital. Br J Clin Pharmacol 2006; 61: 585–91.
22 Mandy B, Koutny E, Cornette C et al. Methodological validation of moni-
toring indicators of antibiotics use in hospitals. Pharm World Sci 2004; 26:
90–5.
23 Marchiset-Ferlay N, Pernot C, Guenfoudi MP et al. Mise en place d’un indi-
cateur d’exposition aux antibiotiques au centre hospitalier université de Dijon.
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